Antibody therapy to prevent coronavirus approved in the UK

17 March 2022
astrazeneca_london_large

Evusheld (tixagevimab/cilgavimab), the coronavirus antibody therapy developed by AstraZeneca (LSE: AZN), has been approved in the UK.

AstraZeneca has already secured US authorization for the long-acting antibody combination, with the US government subsequently ordering additional supplies, for a total of 1.7 million doses, at a value of around a billion dollars.

Unlike rival antibody therapies developed by GlaxoSmithKline (LSE: GSK), Eli Lilly (NYSE: LLY) and Regeneron (Nasdaq: REGN), AstraZeneca’s option is approved for pre-exposure prophylaxis (PrEP), a key differentating factor.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology